MIM1 is an inhibitor of Mcl-1, an antiapoptotic Bcl-2 family protein with a role in cancer. It selectively engages the canonical groove of Mcl-1, inhibiting its ability to bind BH3 domains (IC50 = 4.7 μM). MIM1 induces caspase-3/7 activation and cell death in Mcl-1-dependent leukemia cells.
MIM1 binds to MCL-1 and aids in the modulation of cell death, division and differentiation. MIM1 may be used for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders.
[1]. cohen na, stewart ml, gavathiotis e, et al. a competitive stapled peptide screen identifies a selective small molecule that overcomes mcl-1-dependent leukemia cell survival. chemistry & biology, 2012, 19(9): 1175-1186.
